Physician profile
Riya Desai
NPI 1902641848
$3,676.97
in general payments reported to CMS, 2019-2025
6 companies · $3,559 in 2025
The $3,559 reported for 2025 was more than what 95% of Corneal and Contact Management providers received nationally (typical 2025 total: $227).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $118 · 2025: $3,559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,729 · Travel and Lodging: $1,059 · Consulting Fee: $450 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $225 · Entertainment: $214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,728.71 |
| Travel and Lodging | $1,058.88 |
| Consulting Fee | $450.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $225.00 |
| Entertainment | $214.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Valley Contax, INC. | $2,156.07 | 2025 | |
| Alcon Vision LLC | $593.02 | 2025 | Air Optix, Dailies Total1, Wavelight Ex500 Excimer Laser |
| Bausch & Lomb Americas INC. | $340.88 | 2025 | Zenlens, Infuse, Xiidra |
| Coopervision INC. | $239.20 | 2025 | Clariti Contact Lens, Paragon Crt |
| Johnson & Johnson Vision Care, INC. | $229.41 | 2025 | Acuvue |
| Dompe US, INC. | $118.39 | 2024 | Oxervate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Riya Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.